Profound Medical, Telix Pharmaceuticals Enter Prostate-Care Education Agreement

MT newswire2026/10/09 12:35

08:35 AM EDT, 10/09/2026 (MT Newswires) -- Profound Medical Corp. (PROF) entered into a co-education agreement with Telix Pharmaceuticals (TLX) to educate physicians and prostate cancer centers on the complementary roles of their prostate-care technologies, the company said Friday. The agreement will cover Telix's Gozellix and Illuccix prostate-specific membrane antigen-targeting PET imaging technologies and Profound's MRI-guided, AI-powered, robotically driven and incisionless TULSA-PRO platform across the prostate care continuum. Financial terms were not disclosed. Initiatives include joint participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, as well as the development of educational content, case studies and other materials, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.